Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Ann Neurol 84(6):854872
[12] [13] The systemic availability of orally administered glutathione is poor
Use only reputable products from manufacturers who test for prohibited substances
Additionally, we have developed novel DDX3X PROTAC degraders and compared their anti-tumor efficiency with RK-33, showcasing their great potential and advantages in targeting DDX3X for lung cancer therapeutics
US$ 24.70
US$ 29.95
US$ 21.37
US$ 22.09
US$ 27.46
